论文部分内容阅读
促性腺激素释放激素拮抗剂(GnRHA)自20世纪90年代末开始应用于临床体外受精,但仍存在很多悬而未决的问题。目前尚无理想的拮抗剂用药方案,灵活用药方案似乎要科学合理一些。GnRHA无起爆效应,促排时间短,促性腺激素用量少,使用方便、经济,可有效预防卵巢过度刺激综合征的发生。但可能会导致妊娠率和胚胎种植率降低。对于低反应者是否用拮抗剂方案取代激动剂短周期方案还存在争议。理论上拮抗剂周期应适时添加黄体生成激素,但实践中研究结果不一,是否添加黄体生成激素还无定论。
GnRHA has been used clinically in vitro fertilization since the late 1990s, but many pending problems remain There is currently no ideal antagonist medication regimen, flexible drug regimens seem to be scientifically reasonable. GnRHA no detonating effect, short lead time, gonadotropin dosage, easy to use, economical, can effectively prevent the occurrence of ovarian hyperstimulation syndrome. But may lead to lower pregnancy rates and embryo implantation rates. It is still controversial whether low-responders replace agonist short-cycle regimens with an antagonist regimen. Theoretically, the antagonist cycle should be timely added luteinizing hormone, but in practice the results of different studies, whether to add luteinizing hormone is inconclusive.